North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate
North China Pharmaceutical Co., Ltd. (SHA: 600812) announced that its hexavalent recombinant norovirus vaccine (Hansenula...
SHA: 600812
North China Pharma Wins NMPA Approval for Clinical Trials of Recombinant Tetanus Vaccine
China-based North China Pharmaceutical Group Corporation (SHA: 600812) announced that it has received clinical trial...
North China Pharmaceutical’s Ormutivimab Approved for Pediatric Use in China
North China Pharmaceutical Group Corporation (SHA: 600812) has announced that it has received approval from...